{"id":"brivanib-400-mg-bid","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Abdominal pain"}]},"_chembl":{"chemblId":"CHEMBL270995","moleculeType":"Small molecule","molecularWeight":"441.46"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Brivanib inhibits both FGFR and VEGFR signaling pathways, which are critical for tumor angiogenesis and growth. By blocking these receptor tyrosine kinases, the drug reduces new blood vessel formation to tumors and directly suppresses cancer cell proliferation. This dual-target approach aims to overcome resistance mechanisms that may develop with single-pathway inhibition.","oneSentence":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:50:03.880Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hepatocellular carcinoma (Phase 2)"},{"name":"Advanced solid tumors (Phase 2)"}]},"trialDetails":[{"nctId":"NCT03516071","phase":"PHASE2","title":"A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC","status":"COMPLETED","sponsor":"Zai Lab (Shanghai) Co., Ltd.","startDate":"2017-05-17","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":90},{"nctId":"NCT00798252","phase":"PHASE1","title":"Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-03","conditions":"Advanced Cancer","enrollment":111}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Brivanib 400 mg, BID","genericName":"Brivanib 400 mg, BID","companyName":"Zai Lab (Shanghai) Co., Ltd.","companyId":"zai-lab-shanghai-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Brivanib is a dual inhibitor of fibroblast growth factor receptor (FGFR) and vascular endothelial growth factor receptor (VEGFR) that blocks angiogenesis and tumor cell proliferation. Used for Hepatocellular carcinoma (Phase 2), Advanced solid tumors (Phase 2).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}